Pharsight

Travatan Z patents expiration

TRAVATAN Z's oppositions filed in EPO
TRAVATAN Z Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323630 NOVARTIS Self-preserved aqueous pharmaceutical compositions
Sep, 2027

(3 years from now)

US8388941 NOVARTIS Self preserved aqueous pharmaceutical compositions
Sep, 2027

(3 years from now)

US8268299 NOVARTIS Self preserved aqueous pharmaceutical compositions
Oct, 2029

(6 years from now)

Travatan Z is owned by Novartis.

Travatan Z contains Travoprost.

Travatan Z has a total of 3 drug patents out of which 0 drug patents have expired.

Travatan Z was authorised for market use on 21 September, 2006.

Travatan Z is available in solution/drops;ophthalmic dosage forms.

The generics of Travatan Z are possible to be released after 13 October, 2029.

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 21 September, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of TRAVATAN Z before it's drug patent expiration?
More Information on Dosage

TRAVATAN Z family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic